{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:11:07Z","timestamp":1774354267942,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:00:00Z","timestamp":1636848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ymgmr.2021.100824","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T02:43:36Z","timestamp":1637289816000},"page":"100824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease"],"prefix":"10.1016","volume":"29","author":[{"given":"Alaa","family":"Hamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pronabesh","family":"DasMahapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Lyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Gwaltney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Iaconangelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Modur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Politei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.ymgmr.2021.100824_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","article-title":"Fabry's disease","volume":"344","author":"El-Abassi","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ymgmr.2021.100824_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"10.1016\/j.ymgmr.2021.100824_bb0015","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgmr.2021.100824_bb0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neulet.2016.06.051","article-title":"Mitochondrial DNA haplogroups may influence fabry disease phenotype","volume":"629","author":"Simoncini","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgmr.2021.100824_bb0025","series-title":"Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","year":"2009"},{"key":"10.1016\/j.ymgmr.2021.100824_bb0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13023-021-01894-2","article-title":"Development of the fabry disease patient-reported outcome (FD-PRO): a new instrument to measure the symptoms and impacts of fabry disease","volume":"16","author":"Hamed","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100824_bb0035","series-title":"Good epidemiology practice (GPP). Guidelines for Good Pharmacoepidemiology Pract","year":"2020"},{"key":"10.1016\/j.ymgmr.2021.100824_bb0040","series-title":"IEA guidelines for proper conduct of epidemiological research \u2013 HRSA","year":"2020"},{"key":"10.1016\/j.ymgmr.2021.100824_bb0045","series-title":"International Fabry disease phenotype-genotype database","year":"2020"},{"key":"10.1016\/j.ymgmr.2021.100824_bb0050","series-title":"User's Guide for the SF-36v2 Health Survey","author":"Ware","year":"2007"},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100824_bb0055","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1023\/A:1018831127942","article-title":"Quality of life in persons with irritable bowel syndrome: development and validation of a new measure","volume":"43","author":"Patrick","year":"1998","journal-title":"Dig. Dis. Sci."},{"issue":"9","key":"10.1016\/j.ymgmr.2021.100824_bb0060","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ymgmr.2021.100824_bb0065","series-title":"COSMIN methodology for systematic reviews of patient-reported outcome measures (PROMs): user manual 78. Amsterdam, the Netherlands: COSMIN","author":"Mokkink","year":"2018"},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100824_bb0070","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","article-title":"Intraclass correlations: uses in assessing rater reliability","volume":"86","author":"Shrout","year":"1979","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.ymgmr.2021.100824_bb0075","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1524-4733.2007.00231.x","article-title":"Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: a meta-analytic review","volume":"11","author":"Gwaltney","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.ymgmr.2021.100824_bb0080","series-title":"Test Theory: AUnified Treatment","author":"McDonald","year":"1999"},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100824_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1207\/S15328031US0201_02","article-title":"Repairing Tom Swift's electric factor analysis machine","volume":"2","author":"Preacher","year":"2003","journal-title":"Understanding statistics: Statistical issues in psychology, education, and the social sciences."},{"key":"10.1016\/j.ymgmr.2021.100824_bb0090","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/0013164404272507","article-title":"Gradient projection algorithms and software for arbitrary rotation criteria in factor analysis","volume":"65","author":"Bernaards","year":"2005","journal-title":"Educ. Psychol. Meas."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100824_bb0095","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3102\/10769986022003265","article-title":"Local dependence indexes for item pairs using item response theory","volume":"22","author":"Chen","year":"1997","journal-title":"J. Educ. Behav. Stat."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100824_bb0100","first-page":"254","article-title":"Local dependence diagnostics in IRT modeling of binary data","volume":"73","author":"Liu","year":"2012","journal-title":"Measurement"},{"issue":"7","key":"10.1016\/j.ymgmr.2021.100824_bb0105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/0146621613491456","article-title":"The performance of local dependence measures with psychological data","volume":"37","author":"Houts","year":"2013","journal-title":"Appl. Psychol. Meas."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100824_bb0110","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1348\/000711009X466835","article-title":"Empirically indistinguishable multidimentional IRT and locally dependent unidimensional item response models","volume":"63","author":"Ip","year":"2010","journal-title":"Br. J. Math. Stat. Psychol."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100824_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10705519909540118","article-title":"Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives","volume":"6","author":"Hu","year":"1999","journal-title":"Struct. Equ. Model. Multidiscip. J."},{"key":"10.1016\/j.ymgmr.2021.100824_bb0120","series-title":"Structural Equations with Latent Variables. 1st Edition ed","author":"Bollen","year":"1989"},{"key":"10.1016\/j.ymgmr.2021.100824_bb0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100824_bb0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100824_bb0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100824_bb0140","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.ymgmr.2021.100824_bb0145","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2\u2013eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:22Z","timestamp":1762001542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426921001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":29,"alternative-id":["S2214426921001191"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100824","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100824"}}